Made available in DSpace on 2014-12-17T14:16:34Z (GMT). No. of bitstreams: 1
PaulaCSD_DISSERT.pdf: 2575213 bytes, checksum: b1a82c5d30ff9ebaa0fce4e2c1fef958 (MD5)
Previous issue date: 2011-02-22 / Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico / The study had as objective to evaluate the zinc status by means of dietary intake, zinc in
plasma and in erythrocytes and the metallothionein gene expression in patients with
atherosclerosis in use of rosuvastatin. The research involved 27 adult and elderly patients of
both genders with atherosclerosis that were treated with rosuvastatin (10mg/day) during 4
months. We performed the dosage of lipids, glucose, AST and ALT, ultrasensitive C-reactive
protein (hsCRP), plasmatic and erythrocyte zinc and 1 and 2 metallothionein gene expression.
The assessment of body mass index (BMI) and abdominal circumference (AC) was
performed, besides the analysis of dietary intake of patients. The majority of the evaluated
patients presented overweight, before and after the treatment, with no significant difference
between the times of the study. It was identified that the AC was significantly reduced in the
group (p<0.05) after the intervention. The majority of the patients had intake below the
recommendation of calories and fibers and above recommendation of proteins. The mono and
polyunsaturated fats were adequate for the majority of the patients, however, the saturated fat
and cholesterol were consumed in excess by a great part of the individuals. The intake of zinc
was inadequate, being noticed an inadequacy of 100% in the male gender and of 84% in the
female. After the treatment with rosuvastatin there was a significant reduction in the total
cholesterol (TC) and LDL-c (p<0.01) and no alterations were observed in the HDL-c and
triacylglycerols. It was also verified that the reduction of glycemia (p<0.05) and of hsCRP
(p<0.01). The analysis did not demonstrate significant differences in the plasmatic and
erythrocyte zinc concentration after the treatment. There was, after the treatment, reduction of
the MT1F gene (p<0.05) without, however, occurring significant alterations in the MT2A
gene. The treatment with rosuvastatin was effective in the reduction of TC and LDL-c, and
promoted the reduction of inflammatory marker hsCRP. The zinc in the plasma and
erythrocyte was not altered by the use of the medication and there was a reduction in the
MT1F gene, possibly due to the reduction of inflammation. The majority of patients presented
inadequate intake of zinc and this inadequacy did not have relation with the mineral
parameters in plasma and erythrocytes or with the metallothionein gene expression / O estudo teve como objetivo avaliar o status de zinco por meio da ingest?o diet?tica, zinco no
plasma e nos eritr?citos e a express?o g?nica das metalotione?nas em pacientes com
aterosclerose em uso de rosuvastatina. A pesquisa envolveu 27 pacientes adultos e idosos de
ambos os sexos com aterosclerose que foram tratados com rosuvastatina (10mg/dia) durante 4
meses. Foi realizada a dosagem do perfil lip?dico, glicemia, AST e ALT, prote?na C reativa
ultrasens?vel (PCRus), zinco plasm?tico e eritrocit?rio e express?o g?nica das metalotione?nas
1 e 2. Realizou-se a avalia??o do ?ndice de massa corporal (IMC) e circunfer?ncia abdominal
(CA), al?m da an?lise do consumo alimentar dos pacientes. A maioria dos pacientes avaliados
apresentou sobrepeso, tanto antes como ap?s o tratamento, sem diferen?a significativa entre
os tempos do estudo. Identificou-se que a CA foi reduzida significativamente no grupo
(p<0,05) ap?s a interven??o. A maioria dos pacientes tinha ingest?o abaixo da recomenda??o
de calorias e fibras e acima do recomendado de prote?nas. As gorduras mono e poliinsaturadas
foram adequadas para a maioria dos pacientes, no entanto, a gordura saturada e colesterol
foram consumidos em excesso por grande parte dos indiv?duos. O consumo de zinco foi
inadequado, constatando-se 100% de inadequa??o no sexo masculino e 84% no feminino.
Ap?s o tratamento com a rosuvastatina houve redu??o significativa do colesterol total (CT) e
LDL-c (p<0,01) e n?o foram observadas altera??es no HDL-c e triacilglic?rides. Foi
verificada tamb?m a redu??o da glicemia (p<0,05) e da PCRus (p<0,01). As an?lises n?o
demonstraram diferen?as significativas nas concentra??es de zinco no plasma nem nos
eritr?citos antes e ap?s o tratamento com rosuvastatina. Houve, ap?s o tratamento, redu??o
do gene MT1F (p<0,05) sem, no entanto, ocorrer altera??o significativa do gene MT2A. O
tratamento com rosuvastatina foi efetivo na redu??o do CT e LDL-c, bem como promoveu a
redu??o do marcador inflamat?rio PCRus. O zinco no plasma e nos eritr?citos n?o foi alterado
pelo uso da medicamento e houve uma redu??o do gene MT1F, possivelmente em fun??o da
redu??o da inflama??o. A maioria dos pacientes apresentou consumo inadequado de zinco e
esta inadequa??o n?o teve rela??o com os par?metros do mineral no plasma ou nos eritr?citos
nem com a express?o g?nica das metalotione?nas
| Identifer | oai:union.ndltd.org:IBICT/oai:repositorio.ufrn.br:123456789/13494 |
| Date | 22 February 2011 |
| Creators | Dias, Paula Cristina Silveira |
| Contributors | CPF:17547644449, http://lattes.cnpq.br/1863589790139155, Rezende, Adriana Augusto de, CPF:05410395808, http://lattes.cnpq.br/4245215108740331, Rebecchi, Ivanise Marina Moretti, CPF:08777147898, http://lattes.cnpq.br/7308186244207080, Ong, Thomas Prates, CPF:17089265854, http://lattes.cnpq.br/2216436678930586, Schwarzschild, L?cia de F?tima Campos Pedrosa |
| Publisher | Universidade Federal do Rio Grande do Norte, Programa de P?s-Gradua??o em Ci?ncias Farmac?uticas, UFRN, BR, Bioan?lises e Medicamentos |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis |
| Format | application/pdf |
| Source | reponame:Repositório Institucional da UFRN, instname:Universidade Federal do Rio Grande do Norte, instacron:UFRN |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0318 seconds